anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study aims to elucidate the cognitive underpinnings of language abnormalities in Alzheimer's Disease (AD) using a computational cross-linguistic approach and ultimately enhance the understanding and diagnostic accuracy of the disease.
METHODS: Computational analyses were conducted on language samples of 156 English and 50 Persian speakers, comprising both AD patients and healthy controls, to extract language indicators of AD. Furthermore, we introduced a machine learning-based metric, Language Informativeness Index (LII), to quantify empty speech.
RESULTS: Despite considerable disparities in surface structures between the two languages, we observed consistency across language indicators of AD in both English and Persian. Notably, indicators of AD in English resulted in a classification accuracy of 90% in classifying AD in Persian. The substantial degree of transferability suggests that the language abnormalities of AD do not tightly link to the surface structures specific to English. Subsequently, we posited that these abnormalities stem from impairments in a more universal aspect of language production: the ability to generate informative messages independent of the language spoken. Consistent with this hypothesis, we found significant correlations between language indicators of AD and empty speech in both English and Persian.
INTERPRETATION: The findings of this study suggest that language impairments in AD arise from a deficit in a universal aspect of message formation rather than from the breakdown of language-specific morphosyntactic structures. Beyond enhancing our understanding of the psycholinguistic deficits of AD, our approach fosters the development of diagnostic tools across various languages, enhancing health equity and biocultural diversity.
This is a prospective pilot study in glaucoma patients and a prospective therapeutic trial in ocular hypertensive patients. Patients were recruited from the Temple Ophthalmology outpatient clinic. Primary open-angle glaucoma patients were recruited from those about to have SLT for additional intraocular pressure (IOP) lowering. OHTN patients were recruited from the clinic. The glaucoma patients performed a 5-minute foot massage on a foot massage board and the IOP was checked pre-massage, post-massage and 30, 60, 90 and 120 min post massage. OHTN patients underwent a one-month drop washout and then performed a 5-minute massage using a 3D-printed shoe insert with the identical pressure checks. They then were randomly assigned to wear the shoe insert or a sham insert for one day. IOP was checked before inserting the insert and at the end of the day. The number of steps was recorded each day.
Rapid urbanization and population growth have increased the need for optimizing the location of health services in highly urbanized countries like Kingdom of Saudi Arabia (KSA). This study employs a multiple-criteria decision making (MCDM) approach, e.g., fuzzy overlay technique by combining the P-Median location-allocation model, for optimizing health services. First, a geodatabase, containing public hospitals, road networks and population districts, was prepared. Next, we investigated the location and services of five public hospitals in Jeddah city of KSA, by using a MCDM model that included a fuzzy overlay technique with a location-allocation model. The results showed that the allocated five hospitals served 94 out of 110 districts in the study area. Our results suggested additional hospitals must be added to ensure that the entire city is covered with timely hospital services. To improve the existing situation, we prioritized demand locations using the maximize coverage (MC) location problem model. We then used the P-Median function to find the optimal locations of hospitals, and then combined these two methods to create the MC-P-Median optimizer. This optimizer eliminated any unallocated or redundant information. Health planners can use this model to determine the best locations for public hospitals in Jeddah city and similar settings.
NEW MATERIAL:A compound of formula I (X and Y are H, lower alkyl, lower alkoxyl, OH, halogen or CF3 except when X and Y are H; R1 and R2 are OH or lower alkoxyl), isomer and salt thereof. EXAMPLE:3-(L)-( 1-Ethoxycarbonyl-3-phenylproylamino )-5-carboxymethyl-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one hydrochloride. USE:A remedy for hypertension and other diseases in cardiovascular systems with low toxicity having very strong inhibitory activity against angiotension converting enzymes and long duration of action. PREPARATION:For example, a compound of formula II is reacted with a compound of formula III (Z is halogen; R3 is a protecting group, e.g. alkanoyl group), and the resultant product is subjected to cyclization reaction by heat. The protecting group of R3 is then eliminated, and the resultant compound is reacted with a compound of formula IV and then a compound of formula V to afford the aimed compound of formula I.
A multicenter, randomized, double-blind, placebo-controlled trial (PSOR-4 [NCT03721172]) was conducted in 595 adult subjects with mild to moderate plaque psoriasis (BSA involvement of 2-15%, sPGA score of 2-3 [mild or moderate disease], and PASI score of 2-15). Enrolled subjects had an inadequate response or were intolerant to at least one topical therapy and had not received prior biologic therapy. Subjects were allowed to use unmedicated emollients for lesions on non-scalp areas of the body and non-medicated shampoos for lesions on the scalp.

Subjects were randomized 1:1 to receive either OTEZLA 30 mg twice daily (n = 297) or placebo twice daily (n = 298) for 16 weeks. At Week 16, the placebo group was switched to receive OTEZLA and the OTEZLA group remained on drug through Week 32. The primary endpoint was the proportion of subjects who achieved an sPGA response (defined as an sPGA score of clear [0] or almost clear [1] with at least a 2-point reduction from baseline) at Week 16. Subjects with mild disease (sPGA = 2 at baseline) were required to be clear (sPGA = 0) to achieve an sPGA response. Other evaluated endpoints include the proportion of subjects with a Whole Body Itch NRS response (defined as a ≥ 4-point reduction from baseline) at Week 16 among subjects with a baseline Whole Body Itch NRS ≥ 4 and the proportion of subjects with an ScPGA response (defined as an ScPGA score of clear [0] or almost clear [1] with at least a 2-point reduction from baseline) at Week 16 among subjects with a baseline ScPGA score ≥ 2.

Subjects ranged in age from 18 to 85 years, with an overall median age of 50 years. The mean baseline BSA involvement was 6.4%, the mean baseline PASI score was 6.5, and the proportions of subjects with an sPGA score of 2 (mild) and 3 (moderate) at baseline were 30.6% and 69.4%, respectively.

Clinical Response in Subjects with Mild to Moderate Plaque Psoriasis

The proportions of subjects who achieved an sPGA response, Whole Body Itch NRS response, and an ScPGA response at Week 16 are presented in Table 12.
BACKGROUND: Traumatic brain injury (TBI) affects approximately 69 million individuals annually, often resulting in well-documented complications such as epilepsy. Although numerous studies have been performed on posttraumatic epilepsy (PTE) in adults over the past decade, research on chronic consequences of TBI in children remains limited. Herein, we retrospectively assessed children who had experienced moderate to severe TBI to determine their clinical characteristics and identify associated factors associated with the development of PTE in the pediatric population.
METHODS: The study population comprised children aged 0-18 years who had experienced moderate to severe TBI and underwent treatment at the Children's Hospital of Chongqing Medical University between 2011 and 2021. They were categorized into two groups: the PTE group, comprising individuals diagnosed with PTE within a one-year follow-up period, and the nPTE group, consisting of those who did not develop PTE during the same timeframe. The primary objective was to investigate the clinical characteristics and identify related associated factors. The relationship between various clinical factors and the incidence of PTE was assessed through univariate and multivariate logistic regression.
RESULTS: A total of 132 patients were assessed. Most participants were male (65%) and the age distribution skewed towards younger children, with a median age of 41.0 months (interquartile range: 45.3). Upon their last clinical visit, 64 children (49%) were diagnosed with PTE. Notably, the first posttraumatic seizure predominantly occurred within the first week following the traumatic event. Further analyses revealed that increasing injury severity, as indicated by a lower Glasgow Coma Scale (GCS) score (odds ratio [OR]: 0.78, 95% confidence interval [CI]: 0.54-1.12, p= 0.018), a contusion load ≥3 (OR: 8.1, 95% CI: 2.3-28.9, p= 0.001), immediate posttraumatic seizures (IPTS) (OR: 8.9, 95% CI: 2.5-31.2, p < 0.001), and early posttraumatic seizures (EPTS) (OR: 54, 95% CI: 11-276, p < 0.001), were all significantly associated with a higher risk of developing PTE.
CONCLUSION: This study highlights that the onset of PTE was associated with the markers of injury severity or PTS and identified GCS scores, contusion loads of ≥3, IPTS, and EPTS as independent associated factors significantly associated with the development of PTE.
OBJECTIVES: The goals of this study were to investigate the treatment outcomes of acute thromboembolic occlusion of the superior mesenteric artery (ATOS) and identify prognostic factors after treatment.
METHODS: The clinical data of 62 patients with ATOS between 2013 and 2021 were retrospectively reviewed. Patients were stratified by the treatment strategy, complications and mortality were compared in different group.
RESULTS: Sixty-two consecutive patients were identified with ATOS. The median patient age was 69 years (interquartile range 58-79 years). Endovascular therapy was initiated in 21 patients, and 4 patients received conservative treatment. Open surgery was performed first in the remaining 37 patients. The technical success rates of the endovascular first group and open surgery group were 90.5% and 97.3%, respectively. One patient in the conservative treatment group had progression of ischemia to extensive bowel necrosis. There was no difference in 30-day mortality between these groups. Predictors of 30-day mortality included initial neutrophil count > 12* 103/dL, age over 60 years old and history of chronic renal insufficiency.
CONCLUSIONS: Endovascular treatment or conservative treatment may be adopted in selected patients who do not exhibit signs and symptoms of bowel necrosis, and close monitoring for bowel necrosis is important. The increase in preoperative neutrophil count, age over 60 years old and history of chronic renal insufficiency were poor prognostic factors.
Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
The present invention relates to novel quinazolinone derivatives inhibiting PI3K; a method for preparing the derivatives; and a pharmaceutical composition for treating hematologic neoplasms or liver diseases, containing the quinazolinone derivatives, wherein the novel quinazolinone derivatives have a beneficial effect in the treatment of hematologic neoplasms or liver diseases. In an aspect, there is provided a compound of Formula I or a pharmaceutically acceptable salt thereof:    wherein, X is ¨H, halogen, -CH3, or ¨NH2; and Y is                                                                  linear alkyl or C3-4 cycloalkyl. Particularly, the quinazolinone derivatives inhibit PI3K.delta. with high selectivity compared to that of a conventional anticancer drug of PI3K.delta.  inhibitors, thereby significantly reducing immunotoxicity, or simultaneously inhibit PI3K.delta. and PI3K.gamma., thereby enabling the treatment of autoimmune diseases, and anticancer therapy for blood cancer. These targeted drugs have an advantage of enabling the problem of side effects of a conventional highly toxic anticancer therapy to be resolved.
Continuous stitches will be used for plication during anterior colporrhaphy. Sutures will be at a distance of no more than 0.5 cm. Trimming of the vagina will be performed if necessary. The anterior vaginal skin is closed with continuous 2/0 vicryl sutures.
PURPOSE:An ingestible substance, obtained by containing an angiotensin converting enzyme inhibitory peptide and useful as a health food for preventing hypertension, etc. CONSTITUTION:A peroral ingestible substance obtained by containing 5-60wt% angiotensin converting enzyme inhibitory peptide, e.g. CEI12 (having the amino acid sequence expressed by formula I), CEIbeta7 (formula II), CEI5 (formula III), etc., obtained by digesting casein with trypsin. The substance, together with a carrier, may be formulated into the form of tablet, capsule, powder, granule, etc. The substance may be used as a solid or liquid food, e.g. confectionery, powdered green tea, etc., or favorite food, e.g. alcohol beverage, sports drink, etc. In both cases, the substance is preferably enteric from the viewpoint of preventing hydrolysis of ACE inhibitory peptide and deterioration in activity by gastric fluid. EFFECT:The substance has extremely low toxicity and can be continuously and orally administered for aiming at moderation of hypertension tendency and regulation of blood pressure.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, specifically to otorhinolaryngology and toracal surgery, and can be used for prevention and treatment of chronic cicatrical stenosis of larynx and trachea. To that end, mixture of diprospan (0.5 - 1.0 ml), longidasa (1500-3000 UI), 2% lidocain (0.04 g) and ketorolac (0.03 g) diluted to 5 ml with 10% glucose solution is administered retrosternally, peritracheally. The mixture is administered once a week, a course including 1-3 injections. 3-5 inhalations are performed with compressor nebuliser of longidasa 1500 ME dissolved in 3 ml of broncholytic or mucolytic medicine once a week in intervals between administrations. ^ EFFECT: increased therapeutic efficiency in stenoses treatment and restenosis process prevention due to improved lymph flow, blood flow, microcirculation, tissues trophism, prolonged anaesthesia and lowering of endotoxemia level leading to quick inflammation relief and prevention of excessive development of cicatrical and granulation tissue in larynx and trachea. ^ 3 ex
OBJECTIVES: Adiposity may have a role in the risk of dementia. Fewer studies have focused on the relationship between change in adiposity and cognitive decline. Our study aimed to explore the association between the change in adiposity and cognitive function in Black and White older adults.
METHODS: The participants were 12,204 older adults without cognitive impairment (62.8 ± 8.0 years) in the United States. The percent body mass index change (%BMI change) and percent waist circumference change (%WC change) were measured at 2 in-home visits (first: 2003-2007, second: 2013-2016). Cognitive status was assessed by the Six-Item Screener annually. Memory and executive function were measured by word list learning, MOCA recall and orientation, and letter and animal fluency every 2 years. Logistic regression or linear regression models were used to estimate the relationship between percent change in adiposity and cognitive function.
RESULTS: After 12.7 ± 1.7 years, a greater decrease in %BMI change or %WC change was significantly associated with a higher risk of cognitive impairment. Compared to older adults with -5% ≤ change ≤ 5% from baseline, a significantly higher risk of cognitive impairment and greater loss in memory and executive function were found among those who experienced more than a 10% decline in %BMI change or %WC change. Older adults who experienced a 5%-10% decrease in %BMI change had a higher risk of cognitive impairment and greater loss of memory compared to those with -5% ≤ change ≤ 5%.
DISCUSSION: A greater decrease in %BMI (>5%) and %WC (>10%) change was associated with greater cognitive loss observed over time.
INTRODUCTION: Various evaluation tools have been developed to track the growth of auditory-related behaviours of children with hearing loss during intervention. However, the reliability and validity of currently available outcome measures remain uncertain due to the lack of information on their psychometric properties. A lack of reliable outcome measures may jeopardise intervention quality and affect these children's listening skills progression. This scoping review aims to explore the mechanics of producing or developing an outcome measure either completely new or adapted from the original version that is considered as having robust statistical properties.
MATERIALS AND METHODS: A scoping review was conducted across four databases (PubMed, ScienceDirect, Scopus and Google Scholar). The included articles were written in English, published between January 2010 and June 2023, and specific to predefined keywords. Two independent reviewers screened and selected the final papers using the PRISMScR checklist. A code framework was created to extract information about the publications and conducted by one reviewer. The results were reported using descriptive statistics and narrative synthesis.
RESULTS: The final analysis were conducted on 22 articles out of 452 articles screened. The review identified seven outcome measures presented in various languages. The outcome measures found were the Auditory Behaviour in Everyday Life (ABEL), Functional Listening Index for Paediatric (FLI-P), Infant-Toddler Meaningful Auditory Integration Scale (IT-MAIS), Integrated Scales of Development (ISD), LittlEARS Auditory Questionnaire (LEAQ), Parent's Evaluation of Aural/Oral Performance in Children (PEACH), Parent's Evaluation of Aural/Oral Performance in Children Diary (PEACH Diary), Teachers' Evaluation of Aural/Oral Performance in Children (TEACH) and Parent's Evaluation of Aural/Oral Performance in Children Plus (PEACH+). A total of 13 studies focused on translating, adapting and validating an outcome measure while the remaining investigations validated either the translated or original version of the outcome measures. All original instruments were developed in English and among Western culture, except for the LEAQ which was designed in the German language and for the German population. The outcome measures identified were translated and adapted into Spanish, Turkish, Persian, Hebrew, Arabic, Malay, Yoruba, Polish, Swedish, Hindi, Portuguese, Kannada and Mandarin.
CONCLUSION: All studies performed an extensive evaluation of psychometric properties and feasibility studies to produce an excellent quality of auditory-related behaviour outcome measure for clinical use with the intended population. A new outcome measure, FLI-P, was found to be clinically useful for the primary provider of learning to listen and spoken language training for children with hearing impairment in Malaysia, i.e., the speech-language therapists.
Shade is a stressful factor for most plants, leading to both morphological and physiological changes, and often resulting in increased susceptibility to diseases and pathogen attacks. Our study revealed that the isoflavonoid synthesis pathway was inhibited in alfalfa under shade, resulting in a significant reduction in disease resistance. Overexpression of MsIFS1, a switch regulator in isoflavonoid synthesis, led to a notable increase in endogenous isoflavonoids and enhanced resistance to Pseudomonas syringae pv. tomato DC3000 (Pst. DC3000). Conversely, MsIFS1-RNAi had the opposite effect. Yeast one-hybrid (Y1H) assays revealed that the shade-responsive transcription factor MsWRKY41 could directly bind to the MsIFS1 promoter. This interaction was confirmed through Dual-Luciferase Reporter (Dual-LUC) and Chromatin Immunoprecipitation coupled with quantitative PCR (ChIP-qPCR) assays, both in vitro and in vivo. Overexpression of MsWRKY41 not only enhanced alfalfa's resistance to Pst. DC3000 but also promoted the accumulation of isoflavonoids. Additionally, yeast two-hybrid (Y2H) assays showed that neither MsWRKY41 nor MsIFS1 physically interacted with the Type III effector (T3SE) HopZ1 secreted by Pst. DC3000, suggesting that the MsWRKY41-MsIFS1 module is not a direct target of HopZ1. These findings provide valuable theoretical insights and genetic resources for the development of shade-tolerant alfalfa with enhanced disease resistance.
PROBLEM TO BE SOLVED: To obtain the subject cement excellent in bond strength, mechanical strength, water resistance and biocompatibility, in particular improved in flexural strength as a drawback of cement by including CPSA glass fiber. SOLUTION: This dental cement contains CPSA glass fiber which means CaO-P2O5-SiO2-Al2O3-based glass; wherein the proportions of the respective oxides are pref. as follows: CaO.P2O5 20-65 mol%, SiO2 20-70 mol%, and Al2O3 7-30 mol%. The cement as object to be used is e.g. glass ionomer-based cement, zinc polycarboxylate-based cement, zinc phosphate-based cement, calcium phosphate-based cement. The CPSA glass fiber is preferably used through formulation in the base component of the cement, its amount to be formulated being pref. 5-85 wt.% or 3.5-65 wt.%, based on the base component or the whole cement, respectively.
BACKGROUND: To elucidate the changes in activated complement pathway in the fibrous process of benign prostatic hyperplasia (BPH), we analyzed the correlation between complement component expression and histological types of fibrosis using human BPH tissue.
METHODS: Fifty-six histological BPH patients who underwent prostate needle biopsy at our institution (mean age 68.6 ± 6.5 years), divided into two histological groups, fibromuscular and fibrous, were compared. Inflammatory cell infiltration in BPH tissue was evaluated by immunohistochemical staining using CD45, with complement expression analysis performed using C3, factor B, and C5b-9 antibody, and the occupancy ratio of the stained region was calculated. Further, correlation between the histological types of fibrous components in BPH tissue and lower urinary tract symptoms questionnaires was analyzed.
RESULTS: Twenty-seven (48.2%) and 29 (51.8%) cases were classified in the fibromuscular and fibrous groups, respectively. The proportion of CD45-positive cells in BPH tissue was significantly higher in the fibromuscular group. In complement component analysis, factor B did not significantly differ between groups, while C3 (fibromuscular group; 10.7 ± 8.2%, fibrous group; 16.4 ± 12.7%) and C5b-9 (fibromuscular group; 15.9 ± 6.2%, fibrous group; 17.6 ± 9.2%) were significantly higher in the fibrous group (p = 0.04, p = 0.04, respectively). International Prostate Symptom Score Q5 subscore, indicating slow stream, was significantly higher in the fibrous group (p = 0.04).
CONCLUSIONS: In fibrous BPH with abundant fibrosis, the late complement pathway in addition to alternative pathway was activated compared to fibromuscular BPH. These results suggested that the alternative and late complement pathways were involved in the histological fibrous process of BPH.